3.4.24

Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer

New Haven, CT – March 4, 2024 – Osmol Therapeutics, a privately held biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer,  replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.

“We are pleased to welcome Ron, with his significant oncology drug development expertise, to the Osmol team,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics. “His medical leadership will be invaluable as we advance OSM-0205 into the clinic based on recent U.S. and German regulatory authority feedback on our development program, including clinical plans, nonclinical studies and manufacturing to support the Phase 2 studies.”

“We would also like to express our sincere gratitude to Art for his many contributions during the early stages of development for OSM-0205 and look forward to continuing to work together as he joins Osmol’s Scientific Advisory Board,” concluded Linke.

“I look forward to working with the Osmol team to guide the clinical development of OSM-0205 for the treatment of chemotherapy-induced peripheral neuropathy and chemotherapy-induced cognitive impairment, debilitating conditions with no approved treatment options,” said Dr. Weitzman.

Ron Weitzman, M.D., has held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech and Novartis. Most recently he served as Chief Medical Officer at Tango Therapeutics, where he oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) applications, while leading the clinical and clinical operations teams. Prior to Tango, Dr. Weitzman served as Vice President of Clinical Development at Exelixis, where he had overall responsibility for the strategy and execution of the clinical plan for cabozantinib, a drug therapy for prostate cancer. Dr Weitzman is board-certified by the American Board of Internal Medicine in Medical Oncology.

About OSM-0205
Osmol’s lead therapeutic candidate, OSM-0205, is based on the research of Barbara Ehrlich, PhD, in neuronal calcium sensor-1 (NCS1) at Yale School of Medicine, which is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage. Data from non-clinical studies conducted by Osmol show that pre-treatment with OSM-0205 prevents the pathologic damage caused by these chemotherapy agents.

About Osmol Therapeutics
Osmol Therapeutics is a privately held, clinical stage biopharma company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy  and chemotherapy-induced cognitive impairment based on the ground-breaking work of Barbara Ehrlich, PhD, Professor of Pharmacology, Yale School of Medicine, and Chief Scientific Officer, Osmol Therapeutics. The company’s lead indication will be for the prevention of CIPN related to taxane treatment. As an example of the extent of this condition, up to 80% of taxane-treated patients with breast cancer have been reported to experience CIPN. For more information, please visit https://osmoltherapeutics.com/.

### 

Contact:
Gina Nugent
gina@nugentcommunications.com